Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gene Expression Profiling for M-VAC in Invasive Bladder Cancer
NCT00516750Phase 2
Key facts
- Status
- Terminated
- Start
- Jul 2007
- Primary completion
- Feb 2009
- Countries
- 1
- Sponsor
- Kyoto University
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Conditions
- bladder neoplasm
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, doxorubicin, methotrexate and vinblastine in bladder neoplasm, sponsored by Kyoto University. Primary endpoints: Correlation between gene expression profile and chemotherapy effect and Reduction in original tumor size. Started Jul 2007; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
M-VAC Chemotherapy
Patients receive methotrexate, vinblastine, doxorubicin, and cisplatin.
03
Endpoints
Primary
Correlation between gene expression profile and chemotherapy effect
Reduction in original tumor size
Secondary
Safety of the regimen
Overall Survival Rate
Reduction in size of metastatic lesions
Beyond the preview
Go deeper on NCT00516750.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00516750.